Background Bestrophin-1 (BEST1) gene is associated with a wide range of ocular phenotypes, collectively termed as bestrophinopathy. The aim of the current study was to identify the mutation spectrum of BEST1 in a large cohort of Chinese patients with bestrophinopathy.
Methods Patients clinically suspected of bestrophinopathy were screened using multigene panel testing. All BEST1 variants were confirmed by Sanger sequencing, and validated in the families.
Findings A total of 92 patients (Best vitelliform macular dystrophy (BVMD)=77; autosomal recessive bestrophinopathy (ARB)=15) from 58 unrelated families of Chinese origin and their available family members (n=65) were recruited. Overall, 39 distinct disease-causing BEST1 variants were identified, including 13 novel variants, and two reported variants but novel for ARB. Of them, 14 were associated with ARB, 23 with BVMD and two (c.604C>T and c.898G>A) with both BVMD and ARB. Most mutations associated with BVMD were missense (97.78%), while ARB was associated with more complex mutations, including missense (88.46%), splicing effect (3.85%), and frameshifts (15.38%). BEST1 hotspots were c.898G>A and c.584C>T among BVMD and ARB patients, respectively. Hot regions were located in exons 8, 2 and 6 in BVMD patients, and in exons 5 and 7 in ARB patients. The overall penetrance of BEST1 in our cohort was 71.30%, no de novo mutations were identified.
Conclusion This is the largest study to date that provides major population-based data of the BEST1 mutation spectrum in China. Our results can serve as a well-founded reference for genetic counselling for patients with bestrophinopathy of Chinese origin.
- next-generation sequencing
- mutation spectrum
Statistics from Altmetric.com
F-JG and Y-HQ are joint first authors.
Contributors J-HW and QC conceived and designed the experiments. G-ZX, WL, J-LG, QC, F-JG, J-HW, Y-JZ, PX and Y-HQ collected the clinical samples. F-JG, J-HW, F-YH, J-KL, WL, FC and D-DW analysed sequencing data. J-LG, WL and Y-HQ performed clinical examination of patients and clinical interpretation. F-JG, Y-HQ and J-HW drafted and revised the manuscript. All authors read and approved the manuscript.
Funding This work was supported by the National Natural Science Foundation of China (Grant NSFC81770925, 81770944,81790641, the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences 2018PT32019). The Natural Science Foundation of Guangdong Province (NO.2015A030313472), Shenzhen Engineering Laboratory for Birth Defects Screening, DRC-SZ 750.
Competing interests None declared.
Patient consent for publication Parental/guardian consent obtained.
Ethics approval The current study involving human subjects was approved by the Ethics Committee of the Eye and ENT Hospital of Fudan University, Shanghai, China.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.